Skip To Main Content
Denne hjemmeside er forbeholdt sundhedspersoner, der bor og/eller arbejder i Danmark
Campus
  • Uddannelse
  • Artikel
  • Reumatologi
  • Materiale
  • Vacciner
Campus
  • Uddannelse
  • Artikel
  • Reumatologi
  • Materiale
  • Vacciner
View Full Results

Betydningen af type 2-inflammation*

Forfatter : Sanofi
Editorial Team
Highlight

* Type 2 inflammation hos KOL er defineret ved forhøjet biomarkør. (Eosinofile celler i blodet >300 µL eller >2% eller eosinofile celler i sputum på > 3%)

Type 2 inflammation* kan øge risikoen for eksacerbationer samt lungefunktionsnedsættelse ved KOL4,16

KOL er karakteriseret ved slimproduktion, luftvejsobstruktion og hoste1

lungs

Inflammationen manifesterer sig systemisk og lokalt

systematic
localized
  • Kronisk inflammation resulterer i strukturelle forandringer, herunder forsnævring af luftvejene og nedsat lungeelasticitet1
  • Studier har påvist en sammenhæng mellem inflammation og slimhypersekretion ved luftvejssygdomme såsom KOL14
Highlight

* Type 2 inflammation hos KOL er defineret ved forhøjet biomarkør. (Eosinofile celler i blodet >300 µL eller >2% eller eosinofile celler i sputum på > 3%)

Se efter forhøjede eosinofile celletal i blodet (>300 celler/μL) - en biomarkør for type 2 inflammation* ved KOL1

Highlight

Forhøjet eosinofile celletal i blodet hos KOL-patienter, er en "treatable trait" og markør for type 2 inflammation*1

GOLD reporten fra 2024 anerkender eosinofile celletal i blodet, som en klinisk relevant biomarkør til at identificere KOL med type 2 inflammation*.1

Type 2 inflammation* ved KOL kan involvere flere pathways, cytokiner, og inflammatoriske celler18-23

graph

IL-4, IL-13 og IL-5 er alle type 2 cytokiner som spiller en rolle i KOL

Highlight
Highlight
air-flow
Highlight

* Type 2 inflammation hos KOL er defineret ved forhøjet biomarkør. (Eosinofile celler i blodet >300 µL eller >2% eller eosinofile celler i sputum på > 3%)

aEn alvorlig eksacerbation blev defineret som en indlæggelse på grund af KOL. Eksacerbationerne skulle være med mindst 4 ugers mellemrum for at blive betragtet som separate eksacerbationer.27
bI en kohorte af patienter med EOS >200 celler/μL.26
cGengivet med tilladelse fra the American Thoracic Society. Fritzsching B et al. Am J Respir Crit Care Med. 2015;191(8):902-91325
dAlcian blue PAS-farvning af slim i cellerne i luftvejsepitelet.25
eResultater fra et observationsstudie af 1553 patienter med GOLD spirometri grad 2-4 KOL (postbronkodilaterende FEV1/FVC ratio <0,7, med FEV, >80 % anslået)23
fResultater fra et 1-årigt observationsstudie af 479 patienter med KOL, hvoraf 173 havde
eosinofilniveauer i blodet ≥200 celler/μL og/eller ≥2 % af det samlede antal hvide blodlegemer24

KOL, kronisk obstruktiv lungesygdom; EOS, eosinofile celler; FEV1, forceret udåndingsvolumen på 1 sekund;FVC, forceret vitalkapacitet; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IFN-y, interferon-gamma; ILC2, medfødte lymfoide type-2 celler; MUC5AC, mucin 5AC; PAS, periodic acid-Schiff; TNF-a, tumornekrosefaktor alfa; TSLP, tymisk stromal lymfopoietin

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2024 report). Accessed [February 9, 2024]. https://goldcopd.org/2024-gold-report-2/

  2. Halpin DMG, Dransfield MT, Han MK, et al. The effect of exacerbation history on outcomes in the IMPACT trial. Eur Respir J. 2020;55:1901921. doi:10.1183/13993003.01921-2019

  3. Casanova C, Celli BR, de-Torres JP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017;50:1701162. doi:10.1183/13993003.01162-2017

  4. Yun JH, Lamb A, Chase R, et al; COPDGene and ECLIPSE Investigators. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037-2047.e10. doi:10.1016/j.jaci.2018.04.010

  5. Oshagbemi OA, Franssen FME, van Kraaij S, et al. Blood eosinophil counts, withdrawal of inhaled corticosteroids and risk of COPD exacerbations and mortality in the clinical practice research datalink (CPRD). COPD. 2019;16(2):152-159.

  6. Oshagbemi OA, Burden AM, Braeken DCW, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am J Respir Crit Care Med. 2017;195(10):1402-1404.

  7. Ajithkumar CS 2018

  8. Wu HX, et al. Prevalence and Baseline Clinical Characteristics of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-Analysis and Systematic Review. Front Med (Lausanne). 2019; 6:282.

  9. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662-671 (Leigh 2006)

  10. Leigh R,et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27:964–971.

  11. Schumann DM, et al. Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPD. Chest. 2019; 156:456–465.

  12. Jamieson DB, et al. Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188:187–192.

  13. Alcázar-Navarrete B, et al. Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COP phenotypes. NitricOxide.2016;54:67–72.

  14. Fritzsching B, Zhou-Suckow Z, Trojanek JB, et al. Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung disease. Am J Respir Crit Care Med. 2015;191(8):902-913.

  15. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965-974.

  16. Bélanger M, Couillard S, Courteau J, et al. Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization. Int J Chron Obstruct Pulmon Dis. 2018;13:3045-3054.

  17. George L, Taylor AR, Esteve- Codina A, et al; U-BIOPRED and the EvA study teams. Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. Allergy. 2020;75(2):370-380

  18. Yousuf A, Ibrahim W, Greening NJ, Brightling CE. T2 biologics for chronic obstructive pulmonary disease. J Allergy Clin Immunol Pract. 2019;7(5):1406-1416.

  19. Barnes PJ. Inflammatory endotypes in COPD. Allergy. 2019;74(7):1249-1256.

  20. Oishi K, Matsunaga K, Shirai T, Hirai K, Gon Y. Role of type 2 inflammatory biomarkers in chronic obstructive pulmonary disease. J Clin Med. 2020;9(8):2670. doi:10.3390/jcm9082670

  21. Gabryelska A, Kuna P, Antczak A, Białasiewicz P, Panek M. IL-33 mediated inflammation in chronic respiratory diseases—understanding the role of the member of IL-1 superfamily. Front Immunol. 2019;10:692. doi:10.3389/fimmu.2019.00692

  22. Allinne J, Scott G, Lim WK, et al. IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation. J Allergy Clin Immunol. 2019;144(6):1624-1637.e10.

  23. Calderon AA, Dimond C, Choy DF, et al. Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD. Eur Respir Rev. 2023;32(167):220144. doi:10.1183/16000617.0144-2022

  24. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos D. Targeting key proximal drivers of type 2 inflammation* in disease. Nat Rev Drug Discov. 2016;15(1):35-50.

  25. Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007;119(6):1303-1310.

  26. Doyle AD, Mukherjee M, LeSuer WE, et al. Eosinophil-derived IL-13 promotes emphysema. Eur Respir J. 2019;53(5):1801291. doi:10.1183/13993003.01291-2018

  27. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16-27.

  28. Defrance T, Carayon P, Billian G, et al. Interleukin 13 is a B cell stimulating factor. J Exp Med. 1994;179(1):135-143.

  29. Yanagihara Y, Ikizawa K, Kajiwara K, Koshio T, Basaki Y, Akiyama K. Functional significance of IL-4 receptor on B cells in IL-4– induced human IgE production. J Allergy Clin Immunol. 1995;96(6 pt 2):1145-1151.

  30. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425-437.

  31. Kaur D, Hollins F, Woodman L, et al. Mast cells express IL-13Rα1: IL-13 promotes human lung mast cell proliferation and FcεRI expression. Allergy. 2006;61(9):1047-1053.

  32. Saatian B, Rezaee F, Desando S, et al. Interleukin-4 and interleukin-13 cause barrier dysfunction in human epithelial cells. Tissue Barriers. 2013;1(2):e24333. doi:10.4161/tisb.24333

  33. Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase– and cathepsin-dependent emphysema. J Clin Invest. 2000;106(9):1081-1093.

  34. Garudadri S, Woodruff PG. Targeting chronic obstructive pulmonary disease phenotypes, endotypes, and biomarkers. Ann Am Thorac Soc. 2018;15(suppl 4):S234-S238.

  35. Alevy YG, Patel AC, Romero AG, et al. IL-13–induced airway mucus production is attenuated by MAPK13 inhibition. J Clin Invest. 2012;122(12):4555-4568.

  36. Singanayagam A, Footitt J, Marczynski M, et al. Airway mucins promote immunopathology in virus-exacerbated chronic obstructive pulmonary disease. J Clin Invest. 2022;132(8):e12901. doi:10.1172/JCI120901

  37. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103(6):779-788.

Dette kunne også være af interesse
Reflekter over ny tilgang til KOL

Reflekter over ny tilgang til KOL

At få en forståelse for type 2 inflammation* kan belyse hvorfor nogle KOL-patienter fortsætter med at få eksacerbationer. Se denne video og lær mere.1

Læs mere
Betydningen af eksacerbationer ved KOL

Betydningen af eksacerbationer ved KOL

Læs mere
Livskvalitet og vurdering af symptomer hos KOL-patienter

Livskvalitet og vurdering af symptomer hos KOL-patienter

Læs mere
MAT-BE-2400702